| Hypercalcemia
Rayos vs Miacalcin
Side-by-side clinical, coverage, and cost comparison for hypercalcemia.Deep comparison between: Rayos vs Miacalcin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMiacalcin has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Miacalcin but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Miacalcin
At A Glance
Oral
Daily
Corticosteroid
SC or IM injection
Daily to every 6 hours
Calcitonin receptor agonist
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Osteitis Deformans
- Hypercalcemia
- Osteoporosis, Postmenopausal
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Osteitis Deformans 100 USP Units (0.5 mL) once daily by subcutaneous or intramuscular injection; ensure adequate calcium and vitamin D intake.
Hypercalcemia Start at 4 USP Units/kg every 12 hours SC or IM; increase to 8 USP Units/kg every 12 hours if no response in 1-2 days; may further increase to 8 USP Units/kg every 6 hours if no response after 2 more days.
Osteoporosis, Postmenopausal 100 USP Units (0.5 mL) once daily by subcutaneous or intramuscular injection; ensure adequate calcium (at least 1000 mg/day) and vitamin D (at least 400 IU/day) supplementation.
Contraindications
- Known hypersensitivity to prednisone or any excipient
- Hypersensitivity to calcitonin salmon or any of the excipients (reactions have included anaphylaxis with death, bronchospasm, and swelling of the tongue or throat)
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Most common (>=10%) Nausea with or without vomiting, local inflammatory reactions at injection site
Most common (2-5%) Flushing of face or hands, skin rashes, pruritus of the ear lobes
Serious Hypersensitivity reactions including anaphylaxis, hypocalcemia with tetany and seizures, malignancy (increased incidence observed in meta-analysis)
Postmarketing Bronchospasm, urticaria, influenza-like symptoms, fatigue, edema, arthralgia, musculoskeletal pain, hypertension, abdominal pain, diarrhea, polyuria, dizziness, headache, paresthesia, tremor, visual disturbance
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Calcitonin receptor agonist; calcitonin salmon acts primarily on bone to produce a marked transient inhibition of osteoclast-mediated bone resorption, with additional direct effects on the kidneys increasing excretion of phosphate, calcium, and sodium, and actions on the gastrointestinal tract.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Miacalcin
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Miacalcin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Miacalcin
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
Cost estimate not availableAssistance Fund: Hypophosphatasia (HPP)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MiacalcinView full Miacalcin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.